There’s a need in secondary prevention for personalized risk estimates to motivate patients and guide care, researchers say.

A scientific statement has been published by the American College of Cardiology regarding inflammation and cardiovascular disease.

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...

Iran: Researchers have found in a new study that bariatric surgery, especially sleeve gastrectomy (SG), significantly ...

Despite advancements in treatment and prevention, patients with established atherosclerotic cardiovascular disease (ASCVD) still have particularly high risk of having another heart attack, stroke, or ...

Cardiovascular disease remains one of the dominant non-communicable causes of death in India, contributing substantially to ...

An expert discusses the growing burden of atherosclerotic cardiovascular disease (ASCVD) in the U.S., emphasizing the ...

Combining an antiplatelet with oral anticoagulants in stroke patients with AF and cardiovascular disease slightly lowers ...

Specifically, New Amsterdam will use Caristo’s AI-powered CaRi-Heart and CaRi-Plaque technology to evaluate the efficacy of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s ...

An updated guideline on the management of dyslipidemias has been published by the European Society of Cardiology and European Atherosclerosis Society.